Almost one-third of cases with splenic marginal zone lymphoma (SMZL) express Bcell receptor immunoglobulin (BcR IG) encoded by the IGHV1-2*04 gene, suggesting antigen selection in disease ontogeny. Emerging evidence suggests that IGHV1-2*04 cases comprise a distinct SMZL subtype associated with specific cytogenetic aberrations, gene mutations and an overall worse outcome.
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Traverse-Glehen Here we systematically explored the occurrence of ID in the IG heavy genes of 40 patients with SMZL, including 21 cases expressing IGHV1-2*04 receptors. In order to obtain a more comprehensive view, we also profiled ID in the partner IG light chains in twelve cases. Our findings argue for ongoing antigen activation in SMZL leading to clonal evolution, at least for a substantial proportion of cases. The extensive and distinctive ID observed in IGHV1-2*04 cases compared to cases utilizing other IGHV genes further supports the hypothesis that the former might constitute a distinct subgroup, with important implications for both SMZL subclassification and future clinical and biological research.
Research. 
PATIENTS AND METHODS

Study group
Forty patients with a diagnosis of SMZL from collaborating institutions in Greece, the United Kingdom, Spain, Italy and France were included in the study. The study group included 24 males and 16 females with a median age of 71 years (range, 49-81). For splenectomized patients (n=22), the diagnosis was based on spleen biopsy histopathological findings, following the 2008 WHO Classification criteria(1). For non-splenectomized patients (n=18), the diagnosis was based on the Splenic B-cell Lymphoma Group guidelines (22) . Intraclonal diversification results within the IGHV genes of 4 patients have previously been reported (18) . The study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committees.
PCR amplification and subcloning of IG rearrangements
Immunoglobulin heavy variable-diversity-joining (IGHV-IGHD-IGHJ) gene rearrangements and immunoglobulin kappa or lambda variable-joining (IGK/LV-IGK/LJ) gene rearrangements were PCR amplified as previously reported (18, 21) using: (i) for heavy chain gene rearrangements: IGHV leader primers or consensus primers for the heavy chain variable framework region 1 (VH FR1) and IGHJ-specific primers; and, (ii) for light chain gene rearrangements: consensus primers for the VK FR1/VL FR1 and IGKJ/IGLJ-specific primers (Supplemental Tables 1a-c). The starting material was extracted from peripheral blood (23 cases) or spleen specimens (17 cases); genomic DNA was used in 16 cases whereas for the remaining 24 cases we used cDNA extracted from total cellular RNA. No treatment other than splenectomy had been administered in any of the analyzed cases prior to sample collection. All reactions were performed using the high-fidelity Accuprime Pfx polymerase Tables 1a & 1c) .
Sequence data analysis, interpretation and definitions
Sequences were analyzed using IMGT® databases (23, 24) and the IMGT/V-QUEST tool (25, 26) as well as a suite of in-house, purpose-built algorithms and tools. Each nucleotide mutation in every sequence was recorded, as was the change or preservation of the corresponding amino acid (AA), identified as replacement (R) or silent (S), respectively. AA changes were characterized as 'conservative' or 'non-conservative' following standardized biochemical criteria. Sequences were also analyzed for targeting to the tetranucleotide (4-NTP) motifs RGYW/WRCY (R=A/G, Y=C/T, and W=A/T) as well as the dinucleotide (2-NTP) motifs WA and TW (27) .
Intraclonal diversification was assessed through examination of sequence variation in the V domain, following definitions previously proposed by our group (28) . In brief, all "nonubiquitous" sequence changes from the germline were evaluated and characterized as follows: (a) unconfirmed mutation (UCM): a mutation observed in only one subcloned sequence from the same specimen (unique); and (b) confirmed mutation (CM): a mutation observed more than once among subcloned sequences from the same specimen (partially shared). Amino acid changes resulting from UCMs or CMs are designated by the abbreviations UAA or CAA, respectively. We also defined as trademark mutations those present in only certain subclones of a given case, serving as the defining feature for distinct "branches" (subclones) of the clonal population.
To account for the fact that a mutation is more likely to occur in a FR rather than a CDR simply due to its greater length, each mutation was 'weighted', or normalized, as reported by our group (28) . In particular, normalized mutation frequencies (NMF) were calculated according to the following formula:
Pattern discovery within the VH CDR3
In order to identify common motifs within the VH CDR3, in IGHV1-2*04 rearrangements, we first extracted the VH CDR3 region sequences from all the respective subclones and pairwise compared them in order to end up with one representative for each group of identical VH CDR3 regions. This resulted in a total of fifty-one unique sequences. Since the VH CDR3 sequences differed in their length (range 18-27 AAs), gaps were introduced in shorter rearrangements to facilitate their alignment. The alignment was performed using default settings within the Clustal Omega(29) command line interface tool. Aligned sequences were then processed by applying an adaptive dictionary algorithm (30) . In brief this algorithm operates by first scanning each possible AA combination within a sequence and then checking to see whether a particular combination already exists. An additional computation was performed whereby the position of the AA was taken into consideration, thus enabling the identification of common patterns shared between the VH CDR3 sequences (30) (31) (32) . (18, 20) . In particular, 2/40 (5%) were classified as "truly unmutated" (100% germline identity, GI); 26/40 (65%) were classified as "borderline mutated" (97%-99.9% GI); and finally, 12/40 (30%) were "significantly mutated" (<97% GI). Of note, 19/21 IGHV1-2*04 cases were assigned to the 'borderline mutated' group with only a single case being assigned to each of the other two mutational groups. Detailed information about the IG heavy chain gene repertoire and SHM status is provided in Supplemental Table 1a. ii. Light chains Intraclonal diversification within IG light chain genes was also analyzed for 12/40 cases (Supplemental Tables 1b and 1c 
IGHV1-2*04 rearrangements, especially when only CMs were considered, whereas the opposite was observed for IGHV4-34 gene rearrangements. That said, IGHV1-2*04 rearrangements displayed ID (CMs and UCMs) in all VH sub-regions (Supplemental Table 2c ).
The VH CDR3 was assessed separately and found to display limited ID, essentially restricted to IGHV1-2*04 rearrangements. In particular, we found that 14 Table 3b ).
Analysis of the distribution of point mutations per gene group was meaningful only for IGKV1-8 and IGKV4-1 rearrangements in which a sufficient number of mutations were identified: for these groups, higher NMF values were observed within the CDRs (Supplemental Table 3c ). As evidenced in the VH CDR3, limited ID occurred within the VK or VL CDR3 (8 CMs and 5 UCMs) (Supplemental Table 3d ). Only a minor fraction of the Table 3e ).
iii. Pairs of IGH and IGK or IGL gene rearrangements
The extent of ID was generally concordant between heavy and light chains (Supplemental Table 3f ). Taking only CMs into consideration, 9/12 (75%) cases displayed confirmed ID in either the heavy or the light chain or both. In the case of IGHV1-2*04 cases, with paired heavy/light data, all heavy chain rearrangements displayed CID and where coupled with a light chain rearrangement displaying CID in 2/3 occassions. Moreover, one could notice the concurrent transition of the heavy/light rearrangement from UID to CID state in the IGHV1-2*04/IGKV1-8 case where the rearrangements from two distinct timepoints where subjected to analysis.
Intraclonal diversification analysis at the amino acid level
Seventy-four of 124 CMs (59.6%) identified in the subclones of IGH gene rearrangements resulted in a novel amino acid (AA) change; a similar ratio was observed for UCMs (219/363, Tables 2b and 4a ). The IGHV1-2*04 subcloned rearrangements displayed enrichement for confirmed AA changes (CAA) within the VH FR2, clearly distinguishing them from all other rearrangements (Supplemental Table 4b ). Amongst IG light gene rearrangements, 14/25 CMs (56%) and 34/43 UCMs (79%) resulted in an AA change (Supplemental Table 3b ); AA changes were more frequent within IGKV1-8 and IGKV4-1 gene rearrangements; however the majority were unconfirmed changes (UAA) rather than CAA.
60.3%) (Supplemental
Recurrent amino acid replacements in IGH gene rearrangements
Identical CAAs were shared by subcloned sequences of different rearrangements utilizing the same IGHV gene (Supplemental Table 5 ). In fact, 16 identical CAAs were documented in When patterns were extended to include 3 amino acids, the most frequent tripeptide motif was found to be a phenylalanine-glycine-valine tripeptide (25/51; 49%) followed by a glycine-valine-valine tripeptide (19/51; 37%). Both of these tripeptides stemmed from the aforementioned "VV" and "GV" dipeptide motifs. Thus, our search for common motifs within the VH CDR3 revealed glycine at position 16 and valine at position 17 in our aligned VH CDR3 sequences to be the "parent" amino acids of the most common patterns within IGHV1-2*04 SMZL cases (Supplemental Figure 1) .
Subclonal architecture and temporal dynamics in IGHV1-2*04 rearrangements
The pronounced ID within IGHV1-2*04 rearrangements was also evidenced by the presence of distinct "clusters" of subcloned sequences with "cluster-specific" SHM profiles. Analysis of the SHM patterns in such clusters revealed their common ancestry, but also indicated an early "branching" of the SMZL clone into distinct subclones, perhaps able to evolve along separate pathways through the stepwise accumulation of SHMs. This phenomenon was evidenced in 8/21 IGHV1-2*04 rearrangements, whereas it was not observed in rearrangements utilizing other IGHV genes. Within these latter cases the introduced SHMs were mostly ubiquitous (i.e. present in all subcloned sequences).
The overtime dynamics of ID within the clonotypic IGs in SMZL was assessed by longitudinal analysis of 3 cases in samples collected over a period spanning from 2 to 10 years; 2 cases utilized the IGHV1-2*04 gene while the third case expressed the IGHV3-23 gene. Ongoing SHM was observed within both IGHV1-2*04 rearrangements but not in the IGHV3-23 case nor in the partner light chain of any of these three cases. Of particular interest was the pattern observed in one of the two IGHV1-2*04 rearrangements in which the subcloned sequences from the first timepoint branched into two subgroups each characterized by a "trademark" mutation. This early branching was maintained in the subcloned sequences from the second time-point, however, one of the two groups of subcloned sequences was further branched into three smaller groups by two additional mutations acting as the branching nodes, indicating evolution via a distinct pathway (Figure 4) . 
DISCUSSION
Immunogenetic and functional evidence support a role for antigen in the natural history of SMZL. However, the timing and duration of antigen interactions and their relevance for the evolution of the disease remain elusive. Imprints of ID in the IGH gene rearrangements have been previously reported and interpreted in the context of ongoing SHM (34) (35) (36) (37) . However these studies concerned very few cases, thus hindering definitive conclusions.
In order to address the question as to whether antigen is implicated only in the process of selecting SMZL progenitors or if it is also relevant post-transformation, we conducted a comprehensive subcloning analysis in a series of 40 SMZL cases, by far the largest ever studied for this purpose. Our study was intentionally biased towards cases utilizing the IGHV1-2*04, not only due to its over-expression in SMZL (18) , but also due to increasing evidence suggesting that IGHV1-2*04 gene usage defines a particular subtype of SMZL displaying a distinctive clinicobiological profile with high frequency of both deletion of chromosome 7(3) and KLF2 mutations(12, 13) as well as inferior outcome compared to non-IGHV1-2*04 cases (38) . That said, cases utilizing other IGHV genes were also included in the study, thus offering a comprehensive view of ID across various immunogenetic subgroups of SMZL.
We confirmed ID within the majority of samples and gene groups analyzed, thus supporting the notion that the SHM mechanism remains active post-transformation, further diversifying the clonotypic IG receptors. Importantly, ID was significantly more pronounced in cases carrying IGHV1-2*04 receptors, thus further supporting our previous hypothesis that such cases constitute a unique molecular subgroup of SMZL. Admittedly, the extent of ID differed between IGHV1-2*04 cases, as reflected in different NMF values, which might be related to the fact that these cases differ regarding both their VH CDR3 and partner IG light chains.
These parameters are critical for the overall shape and antigen affinity of any IG and have been found to affect the responses to ongoing antigenic stimulation, leading to distinct SHM profiles (28, 39) .
Affinity maturation through SHM is evolutionarily optimized so that the germline sequences of the IG genes should be able to enhance their stability and viability in the presence of random mutations (40) . In other words, SHM topology is influenced not only by functional constraints but also by the existence of mutable microsequences inside the variable domain, which affect both the introduction of SHM and the operation of repair mechanisms(41). How should one interpret these findings? An important point to consider is that despite the VH CDR3 being the principal determinant of specificity, at least within the primary repertoire, VH CDR3 diversity itself is not sufficient to realize the full potential of antibody diversity (44, 45) . Furthermore, unconventional antigens, such as B-cell superantigens, may be recognized through critical residues outside the VH CDR3, also located within the FRs (46) (47) (48) . From this perspective, the molecular features of ID within the IGHV1-2*04 clonotypic receptors of patients with SMZL seem to go along with the concept of superantigenic interactions within this subgroup of patients, while also underscoring the importance of selecting this particular germline specificity in the SMZL clonogenic progenitor cell repertoire. This argument is further supported by the finding of a lower level of ID in the IG light chain genes of cases with paired IG heavy/light gene analysis, perhaps reflecting IG heavy chain dominance (49, 50) .
In order to obtain more insight into the temporal dynamics of SHM in general and the ID process in particular, we performed longitudinal analysis of 3 SMZL cases, of which 2 expressed IGHV1-2*04 antigen receptors. In these latter cases, ID resulted in a "branching" of the subcloned sequences which was evidenced even at the first timepoint. Additional SHM was observed in each major branch at the second timepoint, raising the possibility that different subclones may evolve across related yet distinct immune pathways.
In conclusion, our present immunogenetic findings seem to justify the claim that IGHV1-2*04 cases constitute a distinct molecular subtype of SMZL, possibly deriving from different Clonal evolution is evidenced since the subcloned sequences of the same case analyzed at different timepoints possess the same ubiquitous mutations and are divided into distinct subgroups based on the presence/lack of "trademark" mutations. Members of each group may also have additional mutations, mainly UCMs.
